Gables Capital Management’s Immunogen Inc IMGN Stock Holding History

Gables Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-277	Closed	-$1K	–	418
2020 Q1	$1K	Buy	+277	New	+$1.21K	﹤0.01%	405

Other funds holding IMGN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Gables Capital Management's IMGN Position: Q2 2020 in Review

Gables Capital Management sold out of Immunogen Inc (IMGN) in Q2 2020, closing a stake of 277 shares — an estimated $1K sold.

Gables Capital Management first reported a position in IMGN in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 189 funds tracked by Wall St. Rank hold IMGN as of Q2 2020.

Gables Capital Management reported no remaining Immunogen Inc position as of Q2 2020 after selling out during the quarter.
Gables Capital Management sold 277 Immunogen Inc shares in Q2 2020, an estimated $1K.
Gables Capital Management first reported a position in Immunogen Inc in Q1 2020 and held it in 1 quarter.
Gables Capital Management's Immunogen Inc position peaked at $1K in Q1 2020.
189 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2020.

Based on Gables Capital Management's 13F filing for Q2 2020, filed 30 Jul 2020.